Login
Login     |     Register     |     Recover Username/Password

News

PG&E Corporation (PCG) Poised to Rejoin Investable Universe

August 22, 2014

Sanford C. Bernstein & Co. Analyst Hugh Wynne says PG&E Corporation (PCG) could soon become more attractive to investors. He says the company has become “exceedingly unpopular” among investors because of the uncertainty surrounding the penalty for the San Bruno gas pipeline explosion. “When you look at the shareholder base, it’s a much smaller group of institutions than the group that owns Edison International,” Wynne says. “I think once that fine is levied by the commission and the company issues stock to offset it, the company’s shares will become attractive to a much wider group of investors.” FOR MORE INFORMATION ON THIS INTERVIEW CLICK HERE...
more

Unveiling of Model X Likely a Catalyst for Tesla Motors Inc (TSLA)

August 20, 2014

Robert W. Baird Analyst Ben Kallo says Tesla Motors Inc (TSLA) is expected to unveil its Model X in the final production format in September or October. Kallo expects the release to be a catalyst for Tesla’s stock. “We’ll start getting reviews around the car, which after couple of delays we expect that Tesla has made significant improvements to the vehicle, and we expect the car to receive, from what we can tell now, similar type of reviews to what the Model S did when they came out, which sets up nicely for lots of positive headlines in the news and gets people thinking that the Tesla is not just a one-trick pony, and we’ll start seeing customer delivery sometime next year, probably early Q2,” Kallo said...
more

Roy Burton, CEO for Dialight Plc (LON:DIA), Presents at Canaccord Genuity Global Growth Conference

August 19, 2014

Roy Burton, CEO for Dialight Plc (LON:DIA), highlighted key drivers that continue to improve company revenues at the 34th annual Canaccord Genuity Global Growth Conference. Of the four primary business groups —components, transportation, signals and lighting — Burton told investors revenue from signals was up by 20%, and lighting now represents 61% of continuing revenue for the first half of 2014. Lighting is the key growth driver, Burton said, showing an increase in revenues of GBP 43 million, or 46% in the first half of this year over 2013. This has resulted in a basic EPS of 10.5 pence, compared against 12.8 pence for 2013. FOR THE LATEST TWST ALTERNATIVE ENERGY AND UTILITIES REPORT CLICK HERE...
more

Francois Nader, President and CEO of NPS Pharmaceuticals, Inc. (NPSP), Presents at Canaccord Genuity Growth Conference

August 19, 2014

Dr. Francois Nader, President and CEO of NPS Pharmaceuticals, Inc. (NPSP), presented financial projections and plans to increase shareholder value at the 34th Annual Canaccord Genuity Global Growth Conference on Thursday. Nader forecasted strong financial results from last year’s launch of Gattex/Revestive in second quarter 2013, which continues to deliver significant growth, with year-over-year 2014 growth on track for 200%-plus. This translates to guided gross sales projected between $100 and $110 million by 4Q2014, Nader said. Nader also announced that the company will expand into its first international market when it begins promoting Gattex/Revestive in the U...
more

Dr. Daniel Gold, President and CEO of MEI Pharma Inc (MEIP), Presents at Canaccord Genuity Growth Conference

August 19, 2014

Dr. Daniel Gold, President & CEO of MEI Pharma Inc (MEIP), updated investors on the status of research involving the company’s three wholly owned drug candidates: Pracinostat, ME-344 and PWT143. All are focused on treating patients with acute myeloid leukemia, myelodysplastic syndrome, or bone marrow cancer, and small cell lung and ovarian cancer respectively, Gold said. Gold reported that Pracinostat continues to show great promise. The drug is in three trials as part of its Phase II study, he said, measuring single agent and multi-combination responses, as well as responses in older patients who are unable to manage the rigors of chemotherapy...
more

Jim Corbett, President and CEO of Alphatec Holdings Inc. (ATEC), Presents at Canaccord Growth Conference

August 18, 2014

Jim Corbett, President and CEO of Alphatec Holdings Inc. (ATEC), announced a new product release at the Canaccord Genuity 34th Annual Growth Conference at the Intercontinental Hotel in Boston. Alphatec Spine, Inc., a wholly owned subsidiary of Alphatec Holdings, Inc., is a global provider of spinal fusion technologies. The company is the sixth largest global spine company, with 80 U.S. patents. The company and its affiliates market products in the U.S. and internationally via a direct sales force and independent distributors, he said. FOR THE LATEST TWST MEDICAL DEVICES REPORT, CLICK HERE. Corbett introduced Arsenal, a new spinal fixation system providing a solution for complex degenerative conditions...
more

Mike Herring, CFO of Pandora Media Inc. (P), Presents at Canaccord Genuity Growth Conference in Boston

August 18, 2014

Mike Herring, CFO of Pandora Media Inc. (P), said new management hires would strengthen the company’s strategies going forward. He was speaking at the Canaccord Genuity 34th Annual Growth Conference at the Intercontinental Hotel in Boston, Massachusetts. Pandora (P) is a streaming service that provides music and comedy programming through Internet connected devices. The company offers personalized stations with the input of a single “seed” – a favorite artist, song or genre from the company’s more than one million available tracks. The company has over 70 million active listeners, Herring said, while 250 million have registered accounts...
more

Steve Skaggs, SVP and CFO, Amtel Corporation (ATML), Presents at Canaccord Genuity Growth Conference in Boston

August 18, 2014

Steve Skaggs, Senior Vice President and Chief Financial Officer of Atmel Corporation (ATML), announced that the company has shifted to a multiyear strategy to focus on the microcontroller market. He was speaking at the Canaccord Genuity 34th Annual Growth Conference at the Intercontinental Hotel in Boston. Atmel is a designer and manufacturer of microcontrollers, capacitive touch solutions, advanced logic, mixed-signal, nonvolatile memory and radio frequency components. Atmel is involved providing system solutions in the industrial, consumer, communications, computing and automotive markets. FOR THE LATEST TWST SEMICONDUCTORS REPORT, CLICK HERE...
more

Ian Clements, Head of IR at Avanir Pharmaceuticals Inc. (AVNR) Presents at Canaccord Growth Conference

August 18, 2014

Ian Clements, the Head of Investor Relations and Corporate Communications at Avanir Pharmaceuticals Inc. (AVNR), said the company is anticipating year-over-year growth of 45% in revenue. He was speaking at the Canaccord Genuity 34th Annual Growth Conference at the Intercontinental Hotel in Boston, Massachusetts. Avanir Pharmaceuticals Inc. is a biopharmaceutical company focused on acquiring, developing and commercializing therapeutic products for the treatment of central nervous system disorders. Its key approved product is Nuedexta, the first FDA-approved treatment for pseudobulbar affect (PBA), acting on sigma-1 and NMDA receptors in the brain and spinal cord...
more

Yves J. Ribeill, President and CEO, Scynexis, Inc. (SCYX), Presents at Canaccord Genuity Growth Conference

August 18, 2014

Yves J. Ribeill, Ph.D, President and Chief Executive Officer of Scynexis, Inc. (SCYX), announced that its SCY-078 is in Phase II at Canaccord Genuity’s 34th Annual Growth Conference at the Intercontinental Hotel in Boston, Massachusetts. Scynexis is a pharmaceutical company aimed at the development and commercialization of anti-infectives to address significant unmet therapeutic needs. Its lead product candidate, SCY-078, is an oral and intravenous (IV) drug for the treatment of serious and life-threatening invasive fungal infections in humans. The company also is targeting the animal health market. FOR THE LATEST TWST BIOTECHNOLOGY REPORT, CLICK HERE...
more

Chris Garabedian, President and CEO, Sarepta Therapeutics (SRPT), Presents at Canaccord Growth Conference

August 18, 2014

Chris Garabedian, President and CEO Sarepta Therapeutics (SRPT), announced that the Phase IIb clinical study on its first product, eteplirsen, will have its results submitted to the FDA by the end of the year, with a launch slated for mid next-year if approved. He was speaking at the Canaccord Genuity 34th Annual Growth Conference at the Intercontinental Hotel in Boston, Massachusetts. Sarepta Therapeutics targets therapies for the RNA molecule. The company’s lead drug development program is for Duchenne muscular dystrophy (DMD), which affects mostly boys and is 100% fatal, with most passing in their 20s. The Phase II tests for eteplirsen show it slows the decline in walking ability for DMD patients who take a six-minute walk test (6MWT)...
more

Georgia Erbez, CFO of Raptor Pharmaceutical Corp. (RPTP), Presents at Canaccord Genuity Growth Conference

August 18, 2014

Georgia Erbez, CFO of Raptor Pharmaceutical Corp. (RPTP), said the company has initiated an 18-month Huntington disease trial. She spoke at the Canaccord Genuity 34th Annual Growth Conference at the Intercontinental Hotel in Boston, Massachusetts. Raptor Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of therapeutics that treat rare, debilitating and often fatal diseases. Among the areas being explored are nephropathic cystinosis, Huntington’s disease (HD), nonalcoholic steatohepatitis (NASH), Leigh syndrome and other mitochondrial diseases. FOR THE LATEST TWST BIOTECHNOLOGY REPORT, CLICK HERE...
more

Todd Davis, CEO, and Chris Power, CFO of Lifelock Inc (LOCK), Present at Canaccord Genuity Global Growth Conference

August 18, 2014

Todd Davis, CEO of Lifelock Inc (LOCK), and Chris Power, CFO, presented the company’s plan to increase shareholder value at the 34th Annual Canaccord Genuity Global Growth conference in Boston last week. With guided revenues expected to reach nearly $500 million by 2014 year-end, the company has seen 30% year-over-year growth since 2010, Power said. Power also reported on the company’s unit economics, noting gross margins at 73% year-end 2013, with an overall goal of 75% to 77% long-term. EBITDA is in the double digits, at 11.4% of revenue, where just three years ago it was in the negative, he said. “We believe in the five-year time frame we can take EBITDA to the 25%-level percentage of income,” Power said...
more

Henk Derksen, SVP and CFO of Belden Inc. (BDC), Presents at Canaccord Genuity Global Growth Conference

August 15, 2014

Henk Derksen, the senior vice president and CFO of Belden Inc. (BDC), presented the company’s financial financial plans to achieve four specific goals over the next three years at the 34th annual Canaccord Genuity Global Growth Conference in Boston this week. The first goal is to grow organic revenue from 0.6% to 4%-6% over the next three years, which includes a commitment to capture market of 2% or better, he said. The second goal focuses on growing operating profit margin from 13.8% in 2013 to 14%-16%. FOR THE LATEST TWST WIRELESS COMMUNICATIONS REPORT, CLICK HERE. The third goal was to continue growing the company’s free cash flow, a goal the company has met over the last nine years...
more

Richard Blickman, President and CEO of BE Semiconductor Industries N. V. (BESI), Presents at Growth Conference

August 15, 2014

Richard Blickman, President and CEO of BE Semiconductor Industries (BESI), discussed the Dutch company’s performance at the 34th Annual Canaccord Genuity Global Growth conference on Wednesday, and he is optimistic about the future of the company. “The industry is expected to grow 12% this year, while we are projecting 15% growth, which shows we are definitely running the company on all cylinders,” Blickman said. In the last 12 months, BE Semiconductor reported revenue and net income of € 304.7 and € 35.7 million respectively, Blickman said. The company has paid € 57 million of dividends and share repurchases since 2011, he added...
more
Page 1 | Next 15 | Page 101
Top Company Interviews
TWST
Register for a Free Account to gain greater access to The Wall Street Transcript right now